No strategy to meet the HCV epidemic.
作者信息
Dalgard Olav, Mauss Stefan
出版信息
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S2. doi: 10.1186/1471-2334-14-S6-S2. Epub 2014 Sep 19.
Abstract
摘要
相似文献
1
No strategy to meet the HCV epidemic.
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S2. doi: 10.1186/1471-2334-14-S6-S2. Epub 2014 Sep 19.
2
HIV and HCV Epidemics: Lessons for Lawyers and Policymakers.
J Law Med. 2019 Apr;26(3):583-594.
3
Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25052. doi: 10.1002/jia2.25052.
4
Hepatitis - a devastating epidemic in Europe.
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S1. doi: 10.1186/1471-2334-14-S6-S1. Epub 2014 Sep 19.
5
Acute hepatitis C virus infection.
Euro Surveill. 2008 May 22;13(21):18879. doi: 10.2807/ese.13.21.18879-en.
6
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Liver Int. 2011 Jul;31 Suppl 2:30-60. doi: 10.1111/j.1478-3231.2011.02539.x.
7
Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S3. doi: 10.1186/1471-2334-14-S6-S3. Epub 2014 Sep 19.
8
The changing epidemiology of hepatitis C virus infection in Europe.
J Hepatol. 2008 Jan;48(1):148-62. doi: 10.1016/j.jhep.2007.07.033. Epub 2007 Nov 5.
9
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875.
10
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Int J Drug Policy. 2007 Oct;18(5):426-32. doi: 10.1016/j.drugpo.2007.01.011. Epub 2007 Feb 15.
引用本文的文献
1
Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa.
J Clin Exp Hepatol. 2018 Dec;8(4):335-341. doi: 10.1016/j.jceh.2018.01.001. Epub 2018 Jan 12.
2
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.
Pharmacoeconomics. 2018 May;36(5):591-601. doi: 10.1007/s40273-017-0604-3.
3
Geographic integration of hepatitis C virus: A global threat.
World J Virol. 2016 Nov 12;5(4):170-182. doi: 10.5501/wjv.v5.i4.170.
4
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.
Int J Drug Policy. 2015 Oct;26(10):922-35. doi: 10.1016/j.drugpo.2015.05.002. Epub 2015 May 17.
本文引用的文献
1
Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S15. doi: 10.1186/1471-2334-14-S6-S15. Epub 2014 Sep 19.
2
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S14. doi: 10.1186/1471-2334-14-S6-S14. Epub 2014 Sep 19.
3
New hepatitis C therapies: the toolbox, strategies, and challenges.
Gastroenterology. 2014 May;146(5):1176-92. doi: 10.1053/j.gastro.2014.03.003. Epub 2014 Mar 12.
4
Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.
J Hepatol. 2014 Feb;60(2):260-6. doi: 10.1016/j.jhep.2013.09.022. Epub 2013 Oct 2.
5
All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study.
J Hepatol. 2013 Jan;58(1):31-7. doi: 10.1016/j.jhep.2012.08.024. Epub 2012 Sep 4.
6
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Liver Int. 2011 Jul;31 Suppl 2:30-60. doi: 10.1111/j.1478-3231.2011.02539.x.
7
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
BMC Public Health. 2009 Jan 22;9:34. doi: 10.1186/1471-2458-9-34.
Zotero 插件